Anatomy-Guided Nanomedicines Aim to Deliver Cancer Drugs Where They Matter Most

Bladder, prostate and kidney cancers together account for more than 2.6 million new diagnoses every year, according to GLOBOCAN 2024 estimates, and they kill well over 700,000 patients annually. Surgery, radiotherapy, chemotherapy, hormone therapy and immune checkpoint blockade have all improved outcomes, yet recurrence, metastasis, drug resistance and treatment-related toxicity continue to frustrate durable disease control. A comprehensive review published in Materials Today Bio now argues that the solution may lie not in better drugs alone, but in a smarter exploitation of anatomy itself. The authors, led by Haoyuan Zheng and Xinxin Li, propose an anatomy-guided framework in which the route a formulation takes to reach a tumor dictates the nanoscale engineering it must possess.

The central insight is deceptively simple. The bladder is a hollow organ whose tumor-bearing lining can be bathed directly in drug through a urethral catheter. The prostate, buried deep in the pelvis, can only be reached by image-guided needle injection through the rectum or perineum. The kidney, a richly vascularized parenchymal organ, offers no luminal access at all, so treatment must ride on arterial catheters, ablation needles or surgical beds. Each route creates a distinct set of barriers, and each barrier demands a different nanomedicine function. The review distills these demands into five requirements: retention, penetration, responsiveness, targeting and therapeutic synergy.

Bladder cancer is the most mature testing ground. Intravesical therapy with Bacillus Calmette-Guérin, mitomycin C, gemcitabine and docetaxel is already standard practice, and the FDA approval of the gene therapy nadofaragene firadenovec and the sustained-release devices UGN-102 and TAR-200 demonstrates that the bladder lumen can support sophisticated local delivery. The problem is physics and physiology: urine dilutes the drug, voiding flushes it away, and the glycosaminoglycan layer over the urothelium resists both adhesion and penetration. Nanomedicine answers with mucoadhesive chemistry. Polyarginine-modified cerium oxide nanozymes, catechol-functionalized alginate particles and thiolated silica nanoparticles all exploit wet-adhesion chemistry borrowed from mussel biology to cling to the bladder wall. Cationic polypeptide nanogels use electrostatic attraction to negatively charged mucosal surfaces, though excessive positive charge risks membrane disruption and inflammation, forcing a careful balance between sticking and toxicity.

Hydrogel depots extend the same principle by forming drug reservoirs inside the bladder lumen, releasing payloads over hours rather than minutes. Some of the most imaginative designs are active rather than passive. Urease-powered nanomotors consume endogenous urea as fuel, propelling themselves across the mucus layer; one such system, loaded with a STING agonist, showed rapid mucosal adhesion and penetration while activating dendritic cells and CD8-positive T cells. Near-infrared light-driven hydrogel nanomotors carrying copper and iron oxide nanoparticles combine mechanical penetration with chemodynamic tumor killing. Hyaluronic acid-decorated carriers exploit the CD44 receptor, overexpressed on many bladder tumors, adding a molecular layer of selectivity on top of organ-level localization. The review emphasizes that surface chemistry can matter as much as drug potency: even the most active agent fails if it is voided before contacting tumor tissue.

Prostate cancer presents the opposite challenge. There is no cavity to instill into, so everything depends on what happens after a needle withdraws. Dense glandular and fibromuscular stroma restricts diffusion, high interstitial pressure impedes spread, and blood and lymphatic drainage can clear injected material within hours. Formulations may pool along the needle track or leak along tissue planes, so the design goal is a controlled balance between retention at the injection site and distribution through the tumor. Docetaxel-conjugated mesoporous silica nanoparticles, injected directly into prostate tumors in xenograft models, illustrate the approach: the silica matrix provides loading capacity and modulates release, concentrating an established taxane where it is needed while sparing bone marrow, nerves and gut from the myelosuppression and neuropathy that limit systemic dosing.

Prostate cancer also offers an unusually strong molecular handle. Prostate-specific membrane antigen, or PSMA, has already transformed imaging and radioligand therapy, and PSMA-targeted mesoporous silica nanoparticles have been shown to deliver docetaxel selectively into prostate cancer cells. The review describes a dual-targeting logic: the needle provides macroscopic localization to the gland, while ligand functionalization adds cellular-level selectivity within it. This matters because prostate cancer is often multifocal and heterogeneous, so procedural targeting alone cannot guarantee uniform coverage. Injectable hydrogels loaded with radiosensitizers, such as an FeGA-based gel combining near-infrared photothermal heating, chemodynamic therapy and low-dose radiotherapy, and PSMA-targeted gold-gadolinium nanoparticles visible on MRI during guided radiotherapy, show how pharmacology can be welded onto existing focal procedures.

The kidney is the hardest target. Renal tumors lack any luminal route, so localized therapy is inseparable from interventional oncology. Because clear cell renal cell carcinoma is typically hypervascular, arterial delivery is attractive: drug-eluting beads and microspheres can combine vascular occlusion with local chemotherapy, and a recent clinical strategy paired embolization with sorafenib and the checkpoint inhibitor envafolimab. But arterial systems must thread a narrow needle, embolize predictably, remain visible on imaging and release drug only where intended; particles that escape the target enter the systemic circulation, while over-embolization can destroy healthy nephrons. Perirenal and postoperative approaches offer alternatives. A curcumin-loaded mesoporous organosilica hydrogel, injected after incomplete thermal ablation and tracked by three-dimensional contrast-enhanced ultrasound, was designed to mop up residual tumor. A biomimetic postoperative hydrogel sequentially releases pirfenidone, siRNA against IDO1 and sorafenib to soften the extracellular matrix and reverse immunosuppression, aiming to prevent recurrence and metastasis after surgery.

Across all three organs, the review identifies a recurring tension: retention and penetration pull in opposite directions. Strong adhesion keeps carriers on the tissue surface but strands the payload above deeper malignant cells; highly mobile particles spread but wash out. Size-transformable carriers that shrink or disassemble in response to acidic pH, enzymes or redox gradients offer one resolution, depositing as a depot and then releasing small diffusible components. Cell-penetrating peptides such as penetratin have improved transurothelial delivery of survivin siRNA in bladder models. Enzyme-responsive prodrugs activated by cathepsin B, abundant in invasive tumors, have shown efficacy in patient-derived bladder cancer xenografts. Externally triggered systems, activated by light, heat, magnetic fields or ultrasound, add temporal precision because clinicians already work with endoscopes, ablation probes and image guidance in these organs.

The pharmacological argument for all this is the therapeutic index. Local delivery can generate tumor-site drug concentrations that would be intolerable systemically, which matters enormously for older patients with reduced renal and hepatic reserve. Concentrating potent immune agonists, including TLR and STING agonists and cytokines such as IL-15, within the tumor microenvironment could convert immunologically cold prostate tumors into inflamed ones or sensitize renal lesions to checkpoint blockade, an in situ vaccination effect, while sparing patients systemic cytokine toxicity. Yet the authors are candid about the caveats. Approved platforms such as UGN-102 and TAR-200 are not nanoparticle systems, and an emerging nanosystem must beat an appropriate local comparator, not merely a systemic drug, before it can claim superiority.

Translational hurdles remain formidable. Laboratory batches must become GMP-manufactured products with tight control of particle size, charge, sterility and release kinetics; intravesical formulations must survive urine and pass through catheters, while embolic carriers demand precise mechanical tolerances. Local pharmacokinetics, not just tumor shrinkage, must become a primary endpoint, measured through imaging, mass spectrometry and radiolabeling. Long-term retention raises its own safety questions, from cystitis and fibrosis to renal parenchymal injury, and subcutaneous xenografts are poor proxies for organs defined by fluid flow, stroma and procedural access. The review’s closing message is that anatomy should guide both the carrier and the clinic: biodegradable, image-visible platforms tailored to each route, developed jointly by materials scientists, imaging specialists and urologic surgeons, offer the most credible path from nanoscale ingenuity to real therapeutic benefit.

Subject of Research: Localized, anatomy-guided nanomedicine delivery for bladder, prostate and kidney cancers

Article Title: Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation

Article References: Zheng, H., Yuan, Y., Zhang, X., Li, H., Wang, W., Chen, Y., Nie, S., Bi, J., Sun, J., & Li, X. (2026). Localized nanomedicine for urologic cancers: anatomy-guided design and clinical translation. Materials Today Bio, 41, Article 103740. https://doi.org/10.1016/j.mtbio.2026.103740

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103740

Keywords: nanomedicine, bladder cancer, prostate cancer, kidney cancer, drug delivery, intravesical therapy, hydrogels, nanoparticles, PSMA targeting, immunotherapy, interventional oncology, clinical translation